Rat's Rant: What's hot, what's not and ... more biotech winners
Oct 3, 2019
Oct 3, 2019 |
7 min
Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.
Actinogen’s shares surge 460% after Xanamem success
Oct 2, 2019
Oct 2, 2019 |
4 min
Actinogen Medical (ASX:ACW) released extremely promising results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial.
Rat's Rant: What's hot, what's not and... the Bali anniversary
Oct 2, 2019
Oct 2, 2019 |
10 min
Actinogen closed up 466% to finish at 5.1c on $15.8 million stock traded. The company announced results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The results demonstrate a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.
